Establishment Labs (ESTA) Expected to Post Earnings on Thursday

Establishment Labs (NASDAQ:ESTA) is projected to post its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to announce earnings of ($0.2568) per share and revenue of $66.81 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:30 AM ET.

Establishment Labs (NASDAQ:ESTA) last announced its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.05). The business had revenue of $67.54 million during the quarter, compared to the consensus estimate of $65.79 million. During the same quarter in the prior year, the business earned ($0.57) EPS. The company’s revenue was up 31.7% on a year-over-year basis. On average, analysts expect Establishment Labs to post ($1.08) EPS for the current fiscal year and ($0.01) EPS for the next fiscal year.

Establishment Labs Stock Performance

NASDAQ:ESTA opened at $66.95 on Wednesday. The company has a 50-day moving average of $67.51 and a 200-day moving average of $72.38. Establishment Labs has a twelve month low of $47.00 and a twelve month high of $97.59.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on ESTA shares. Mizuho upped their price target on Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. Canaccord Genuity Group set a $105.00 target price on Establishment Labs in a report on Thursday, August 6th. Citigroup upgraded Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 price target for the company in a research report on Thursday, August 13th. JPMorgan Chase & Co. raised their target price on shares of Establishment Labs from $84.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Finally, Stifel Nicolaus set a $85.00 target price on shares of Establishment Labs and gave the stock a “buy” rating in a research report on Wednesday, October 14th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $96.11.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a medical technology company focused on women’s health and the breast aesthetics market. The company develops, manufactures and commercializes breast implants and related technologies designed for breast augmentation, reconstruction and revision procedures.

Its product portfolio includes the Motiva line of breast implants, which incorporates the company’s proprietary implant materials, surface technologies and design features. Establishment Labs also offers Motiva Flora tissue expanders for use in breast reconstruction and has developed Mia Femtech, a minimally invasive breast enhancement procedure intended to provide a less invasive alternative to traditional augmentation techniques.

Founded in 2004, Establishment Labs is headquartered in Costa Rica and serves physicians, hospitals and patients in international markets.